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Open access under CC BYThis study reports the preparation and characterization of cysteine-terminated B-domain (Bd-cys) of
Staphylococcus aureus protein A, in combination with immunoglobulin G (IgG) antibodies directed against
the q1 and a1 subunits of GABAA receptors, for localizing reagents of interest to the target receptor. A
cysteine residue was inserted at the C terminus of the cysteine-lacking B-domain (Bd) and used for con-
jugating maleimide-containing compounds. As determined by enzyme-linked immunosorbent assay
(ELISA), binding of a Bd-cys-S-ﬂuorescein conjugate to polyclonal guinea pig anti-GABAA-q1 and rabbit
anti-GABAA-a1 IgG was similar to that exhibited by full-length protein A. Surface plasmon resonance
analysis of the interaction of Bd-cys-S-PEG3400-biotin conjugate (where PEG is polyethylene glycol) with
anti-GABAA-q1 and anti-GABAA-a1 yielded KD values of 6.4 ± 1.9 and 0.4 ± 0.1 nM, respectively. Fluores-
cence anisotropy analysis of the binding of Bd-cys-S-ﬂuorescein to the two antibodies yielded EC50 values
of 65 and 18 nM, respectively. As determined with biotin-reactive ﬂuorescent reagents, Bd-cys-S-
PEG3400-biotin speciﬁcally bound to the plasma membrane of Xenopus laevis oocytes that expressed
a1b2c2 or homomeric q1 GABAA receptors and were pretreated with the corresponding anti-GABAA
IgG. The IgG-binding speciﬁcity and high afﬁnity of Bd-cys conjugates illustrate the potential of these
conjugates, in combination with a selected IgG, to localize compounds of interest at speciﬁc cell surface
proteins.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license. Staphylococcal protein A (SpA),1 a cell wall-associated protein of
Staphylococcus aureus bacteria [1], protects S. aureus against the
host’s immune system by binding to host antibodies [2–5]. SpA con-
sists of a tandem sequence of ﬁve homologous repeats termed
(sequentially from the N terminus) domains E, D, A, B, and C [6–8].
Each of these domains is arranged as three helices [5,9] and binds
to the Fc fragment of immunoglobulin G (IgG) [5,10,11]. The B-
domain (Bd), a 58-amino acid segment (7 kDa) that lacks cysteine
residues, has been studied extensively as a representative domain of
SpA. The similar IgG-binding afﬁnity of Bd and parent SpA [5,11–13],
together with Bd’s ease of bacterial expression and high solubility,g).
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-NC-ND license.has motivated interest in designing afﬁnity reagents based on the
Bd structure [2,12,14–17].
The robust IgG-binding activity of Bd, along with its small size
and deﬁned structure, makes Bd, in combination with an IgG direc-
ted against the ectodomain of a cell surface protein, a potentially
versatile scaffold for localizing reagents at the target protein. Our
motivation for investigating such an approach comes, in particular,
from recent studies demonstrating the light-controlled activation
or blockage of ion channels by photosensitive analogs of channel
ligands that are anchored to a mutant (cysteine-substituted) form
of the channel [18–20]. That is, conjugating Bd with a physiologi-
cally active analog of the channel ligand, and interfacing the Bd/
ligand conjugate with an IgG that binds to the channel’s ectodomain,
might enable modulation of the activity of the native ion channel,
avoiding the need to express a mutant (i.e., anchoring) form of the
channel in the target cell. Mazzucchelli et al. [21], in a recent study
addressing the targeting of HER2 membrane receptors with mag-
netic beads, conjugated the beads with a form of Bd that had been
modiﬁed to contain multiple cysteine residues (which served as
the bead anchoring site), interfaced the Bd/bead conjugate with a
monoclonal anti-HER2 antibody, and, with use of ﬂuorescein iso-
thiocyanate (FITC)-labeled secondary antibody directed against
the monoclonal antibody, demonstrated HER2 receptor labeling. 
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engineered Bd as an IgG-associated scaffold for targeting ion chan-
nel proteins.
GABAA receptors, an abundant and widely distributed class of
heteropentameric ion channels that are gated by the neurotrans-
mitter c-aminobutyric acid (GABA) and mediate neural signaling
at numerous locations in the central nervous system (CNS), includ-
ing the retina, are a logical target for physiological modulation by a
ligand localized at the receptor’s ectodomain (cf. Refs. [18–20]).
Among the 19 known subunits of GABAA receptors are a1, a com-
ponent of the a1b2c2 GABAA subtype found in many neural tissues
[22,23], and q1, a component of GABAA-q receptors (also known as
GABAC receptors) whose distribution includes multiple locations
within the retina [23–26]. As a step toward developing a ligand-
anchoring system for GABA receptors, we have prepared a cys-
teine-terminated form of Bd (here termed Bd-cys) and conjugated
Bd-cys with maleimide-terminated test reagents. The experiments
employed a single cysteine inserted at the end of Bd’s third a-helix,
a site distinct from the Fc-binding positions on the ﬁrst and second
a-helices [2,27]. The absence of native cysteine residues in Bd [12]
avoids the possibility of unwanted intramolecular disulﬁde linkage
to the introduced cysteine [21]. The introduced cysteine is, how-
ever, capable of forming intermolecular disulﬁde linkages with an-
other cysteine-terminated Bd, forming a Bd-cys dimer. With the
use of appropriate IgG antibodies, we tested the ability of com-
plexes consisting of IgG and Bd-cys-tethered reagents to interact
with GABAA q1 and a1 subunits.Materials and methods
Preparation of SpA, Bd, and Bd-cys
Plasmid DNA from Escherichia coli with the pGX2907 plasmid
containing the S. aureus genome, including the full SpA sequence
(American Type Culture Collection, ATCC 39344, Manassas, VA,
USA; SpA gene NCBI accession number J01786), was used as a tem-
plate for polymerase chain reaction (PCR) preparation of DNA frag-
ments coding for wild-type SpA and wild-type Bd. PCR was
performed using Pfu polymerase (Promega, Madison, WI, USA)
and primers designed to allow cloning of the PCR products into
the Champion pET-100 TOPO cloning and expression system (Invit-
rogen by Life Technologies, Carlsbad, CA, USA), which features the
addition of a hexahistidine fusion tag at the N terminus followed
by an enterokinase cleavage site to the protein of interest. Primers
were as follows: SpA (forward: 50-CAC CGC GCA ACA CGA TGA A-30;
reverse: 50-TTA TAG TTC GCG ACG ACG TCC A-30); Bd (forward: 50-
CAC CGC TGA TAA CAA ATT C-30; reverse: 50-CTA TTT TGG TGC TTG
TGC ATC-30). PCR products were ligated to a TOPO plasmid and
transformed into XL-1 One Shot TOPO competent cells, sequenced,
and subcloned. In addition, the TOPO plasmid containing the cod-
ing sequence for Bd was used as a template for preparation of Bd
containing cysteine at the C terminus. The procedure for cysteine
addition was similar to that described above, with the following
primers (cys codon underlined): forward, 50-GCA CAA GCA CCA
AAA TGT TAG AAG GGC GAG CTC-30; reverse, 50-GAG CTC GCC
CTT CTA ACA TTT TGG TGC TTG TGC-30.
Plasmid DNA of the SpA, Bd, and Bd-cys clones was transformed
into BL-21 star E. coli for protein expression. Lysis of the cell pellets
was performed using the BugBuster with Benzonase protein
extraction kit (Novagen/EMD Biosciences, Madison, WI, USA) with
lysozyme and protease inhibitor cocktail added. Proteins were
puriﬁed from the supernatant by afﬁnity chromatography using
HiTrap afﬁnity columns (GE Healthcare, Piscataway, NJ, USA). Prior
to analysis by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE, 4–20% acrylamide gradient, Bio-Rad,Hercules, CA, USA), sample aliquots were prepared in buffer that
either contained 5% (v/v) b-mercaptoethanol (b-ME) (reducing buf-
fer) or lacked b-ME (nonreducing buffer). Gels were then run and
stained by Coomassie blue.
Preparation of Bd-cys conjugates
Because afﬁnity-puriﬁed Bd-cys consisted largely of dimers
linked by a disulﬁde bond (see Results), linkage of Bd-cys to
the investigated ligands ﬂuorescein (FL)-5-maleimide (Fisher
Scientiﬁc, Pittsburgh, PA, USA) andmaleimide-PEG3400-biotin (where
PEG is polyethylene glycol) (Laysan Bio, Arab, AL, USA) was carried
out under reducing conditions. The FL-5-maleimide and malei-
mide-PEG3400-biotin conjugates were prepared by adding 200 ll
of 6 lM (largely dimerized) Bd-cys to each of several wells of a
HIS-Select high-capacity nickel-coated plate (Sigma–Aldrich, St.
Louis, MO, USA) and incubation overnight at 4 C. Following three
washes with TBST buffer (Tris-buffered saline with Tween 20:
10 mM Tris, 150 mM NaCl, and 0.1% Tween 20), 200 ll of freshly
prepared 100 mM dithiothreitol (DTT) reducing agent in water
was added to the empty wells, and the plate was incubated for
40 min at 37 C. Immediately following ﬁve washes with TBST
(5 min total), 120 lM of thiol-reactive FL-5-maleimide or malei-
mide-PEG3400-biotin was added, forming the thioether product
Bd-cys-S-FL or Bd-cys-S-PEG3400-biotin, respectively. The plate
was incubated for 2 h at room temperature and then washed three
times with TBST. The conjugate was removed from the plate by
incubation with 500 mM imidazole buffer for 20 min at room tem-
perature. Bd-cys conjugate solutions were then pooled, concen-
trated to 1 to 2 mg/ml, and dialyzed against phosphate-buffered
saline (PBS); aliquots were then prepared in reducing buffer (5%
b-ME) or nonreducing buffer and analyzed by SDS–PAGE. Experi-
ments were also conducted on preparations that, by design, were
dominated by Bd-cys dimer. FL-labeled Bd-cys dimer conjugate
was prepared by FL labeling of HiTrap Ni-column puriﬁed Bd-cys
dimer (4–6 FLs/protein) and puriﬁcation according to the manufac-
turer’s instructions, using the FluoroTag FL conjugation kit (FITC1-
1KT, Sigma–Aldrich). The FL-labeled product was concentrated to 1
to 2 mg/ml and dialyzed against PBS. This FL-labeled Bd-cys dimer
was then analyzed by SDS–PAGE under reducing or nonreducing
conditions.
Enzyme-linked immunosorbent assay
The interaction of Bd-cys-S-FL monomer and of FL-labeled Bd-
cys dimer with IgG was tested using an enzyme-linked immuno-
sorbent assay (ELISA) similar to that described previously [12].
Wells of HIS-Select Ni plates were incubated overnight at 4 C with
200 ll of 100 nM afﬁnity-puriﬁed Bd-cys dimer, FL-labeled Bd-cys
dimer, Bd-cys-S-FL monomer, SpA protein, or TBST buffer control
(nine wells for each preparation). After three washes with TBST,
three wells containing each preparation were supplemented with
200 ll of 0.5 lg/ml horseradish peroxidase (HRP)-conjugated gui-
nea pig IgG (Rockland Immunochemicals, Gilbertsville, PA, USA)
in binding buffer (TBST + 1% [w/v] bovine serum albumin) and
incubated for 2 h at room temperature. An additional three wells
of each preparation were incubated with 200 ll of 0.5 lg/ml
HRP-conjugated rabbit IgG (Rockland Immunochemicals) in
binding buffer, and three wells of each preparation were similarly
incubated with binding buffer alone (TBST control wells). Wells
were washed three times with TBST buffer, then 200 ll of 2,20-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) liquid
substrate (Sigma–Aldrich) was added, and the plate was incubated
at room temperature for 30 to 40 min. Three separate wells re-
ceived the ABTS substrate only (i.e., no protein preparation and
no antibody) and were termed blank wells. Raw absorbance values
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can Group, Männedorf, Switzerland). For each well, net absorbance
was deﬁned as A405 (sample well) – A405 (blank well).
Surface plasmon resonance
The binding of Bd-cys-S-PEG3400-biotin to anti-GABAA-q1 and
anti-GABAA-a1 antibodies was analyzed by surface plasmon reso-
nance (SPR, Biacore T100, GE Healthcare). All SPR experiments
were performed at room temperature. In the ﬁrst type of experi-
ment, which was designed to establish an antibody-binding proﬁle,
Bd-cys-S-PEG3400-biotin was immobilized on a ﬂow cell of a pre-
coated streptavidin biosensor chip (0.75–1.5 lg/ml) for 60 s. This
immobilization step led to an increase of approximately 2350 re-
sponse units (RU). Guinea pig anti-GABAA-q1 IgG [28], rabbit
anti-GABAA a1 IgG (Abcam, Cambridge, MA, USA), or control anti-
bodies (rat IgG2a [Abcam], chicken immunoglobulin Y [IgY,
Abcam], or anti-insulin chicken IgY [Sigma–Aldrich]) were loaded
into the ﬂow cell (0.03 mg/ml) at a rate of 10 ll/min. The chip
was then washed with HBS-EP+ buffer (GE Healthcare) for 20 to
30 min, and 10 mM glycine buffer (pH 2.0) was added for 60 s to
dissociate bound antibody prior to addition of the next antibody.
The second type of experiment was designed to determine dissoci-
ation constants (KD values), association rate constants (ka values),
and dissociation rate constants (kd values) for the interaction of
Bd-cys-S-PEG3400-biotin with antibody. Here, Bd-cys-S-
PEG3400-biotin was immobilized on the precoated streptavidin
biosensor chip with the application of 40 nM solution at 10 ll/
min for 120 s; this produced a response of approximately 50 to
60 RU. Then, guinea pig anti-GABAA-q1, rabbit anti-GABAA-a1, or
(as controls) rat IgG2a or chicken IgY was added to the ﬂow cell
in triplicate at concentrations of 20, 10, 5, 2.5, 1.25, and
0.625 nM for 240 s, yielding maximum responses of approximately
100 and 200 RU for anti-GABAA-q1 and anti-GABAA-a1, respec-
tively. A wash with 10 mM glycine buffer (pH 2.0) was performed
after each run to dissociate bound antibody. Raw sensograms with-
in each experiment (triplicate samples for each of the six antibody
concentrations) were analyzed by Langmuir 1:1 binding kinetics
using Biacore T100 evaluation software to obtain ﬁtted values of
KD, ka, and kd. For each parameter, values obtained in three sepa-
rate experiments of a given type were analyzed to yield the
mean ± standard deviation (SD).
Fluorescence anisotropy
The binding of Bd-cys-S-FL and FL-labeled Bd-cys dimer to anti-
GABAA-q1 and anti-GABAA-a1 antibodies was also analyzed by
ﬂuorescence anisotropy (FA, POLARstar OPTIMA Microplate Read-
er, BMG Labtech, Cary, NC, USA). Each experiment testing guinea
pig anti-GABAA-q1 IgG and rabbit GABAA-a1 IgG, as well as rat
IgG2a and chicken IgY controls, involved study of a group of 42
mixtures. Each mixture, 50 ll in volume, contained 15 nM FL-
labeled Bd-cys conjugate (Bd-cys-S-FL or FL-labeled Bd-cys dimer)
and antibody at a concentration ranging from 0.078 to 200 nM (14
different concentrations, triplicate samples for each concentra-
tion). In addition, as control experiments, groups of samples (30
mixtures, each 50 ll in volume, per group) containing 15 nM ubiq-
uitin-FL and anti-GABAA-a1, rat IgG2a, or chicken IgY at concentra-
tions ranging from 1.25 to 200 nM (triplicates at each
concentration) were prepared. The mixtures were incubated over-
night at 4 C, added to a 96-well microplate, and analyzed by FA.
Using MARS data analysis software (BMG Labtech), a four-
parameter curve was ﬁtted to the data set. For both Bd-cys-S-FL
and FL-labeled Bd-cys dimer, binding to the anti-GABAA-q1 and
anti-GABAA-a1 antibodies was analyzed in two FA experiments,
each of the type just described. The excursions of the ﬁttedfour-parameter curves in these experiments (i.e., the vertical
[ordinate] distances between the lower and upper asymptotes of
the ﬁtted curves) were as follows (in units of milli-anisotropy
[mA]): 43 and 49 for (Bd-cys-S-FL, anti-GABAA-q1), 40 and 42 for
(Bd-cys-S-FL, anti-GABAA-a1), 78 and 83 for (FL-labeled Bd-cys di-
mer, anti-GABAA-q1), and 12 and 11 for (FL-labeled Bd-cys dimer,
anti-GABAA-a1). For both Bd-cys-S-FL monomer and FL-labeled
Bd-cys dimer, there was no change in mA with varying antibody
concentrations when the Bd-cys preparation was incubated with
either rat IgG2a or chicken IgY. Similarly, there was no change in
mA with antibody concentration for the preparations consisting
of (ubiquitin-FL, anti-GABAA-a1), (ubiquitin-FL, rat IgG2a), or
(ubiquitin-FL, chicken IgY). Each data point from the experiment
was referenced to the minimum (i.e., low-concentration asymp-
totic) value of the ﬁtted curve and normalized to the excursion of
this curve. The referenced, normalized data obtained in each
experiment were averaged. Using OriginPro software (OriginLab,
Northampton, MA, USA), the averaged data were then analyzed
through the equation
y=y0 ¼ x=ðxþ EC50Þ; ð1Þ
where y/y0 is the normalized anisotropy value at a given concentra-
tion of antibody, x is the antibody concentration, and EC50 is a ﬁtted
parameter.
Oocyte preparation and ﬂuorescence imaging
All animal procedures conformed with institutional policies and
with the Statement for the Use of Animals in Ophthalmic Research
adopted by the Association for Research in Vision and Ophthalmol-
ogy. Xenopus laevis oocytes expressing human q1 GABAA or a1b2c2
GABAA receptors (a1, b2, and c2 subunits of rat, rat, and human,
respectively) were prepared as described previously [25,29,30].
Brieﬂy, messenger RNA (mRNA), obtained for each selected se-
quence from in vitro transcription (mMessage mMachine, Ambi-
on/Applied Biosystems by Life Technologies, Austin, TX, USA)
from linearized complementary DNAs (cDNAs), was injected into
the oocytes (Drummond Nanoject II, Drummond Scientiﬁc,
Broomall, PA, USA). Oocytes were analyzed for GABA receptor
expression after 24 to 72 h of incubation in physiological saline
(100 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES,
and 10 mM glucose, pH 7.2–7.4) containing 0.1 mg/ml gentamicin
at 16 C. Immunoﬂuorescence labeling of oocytes expressing either
GABAA q1 or GABAA a1b2c2 receptors and nonexpressing control
oocytes involved, sequentially, a blocking step with 10% fetal bo-
vine serum and 1% bovine serum albumin diluted in physiological
saline (1 h, room temperature), three or four washes with physio-
logical saline, and a 1-h incubation at room temperature with
20 lg/ml primary antibody (guinea pig anti-q1, rabbit anti-a1) or
in the absence of antibody as a control. Following three or four
washes with physiological saline, oocytes were incubated for 1 h
at room temperature either with 100 nM Bd-cys-S-PEG3400-biotin
with streptavidin-DyLight 488 (Fisher Scientiﬁc) or with 100 nM
FL-conjugated Bd-cys dimer. Following six washes, oocytes were
visualized and imaged using a Leica DM-IRE2 confocal microscope
(Leica Microsystems, Buffalo Grove, IL, USA) at 20 magniﬁcation
[28,29].Results
Preparation and cysteine reactivity of Bd-cys monomer
The Bd component of the desired conjugate consisted of mono-
meric Bd containing a terminating cysteine, to which the test li-
gand was attached. Although the absence of other cysteines in
Fig.2. ELISA for binding of Bd-cys preparations and SpA to HRP-conjugated guinea
pig IgG (HRP-gp-IgG) and HRP-conjugated rabbit IgG (HRP-rbt-IgG). Net absorbance
(sample minus blank) data were obtained at 405 nm and are indicated as
means ± SDs of triplicate values. (A) Bd-cys-S-FL and SpA binding versus TBST
control. (B) Bd-cys dimer, FL-labeled Bd-cys dimer, and SpA versus TBST control. For
both of the investigated IgGs, net absorbance obtained with the Bd-cys and SpA
preparations in all cases exceeded that exhibited by the corresponding TBST control
(P < 9.0  104).
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formation, Bd-cys monomers were capable of intermolecular disul-
ﬁde linkage (i.e., dimerization). Thus, the preparation of mono-
meric Bd-cys necessitated the reduction of dimerizing disulﬁde
bonds that formed upon the expression and afﬁnity puriﬁcation
of the protein. To determine the extent of contamination of conju-
gated Bd-cys preparations (Bd-cys-S-FL, FL-labeled Bd-cys dimer,
and Bd-cys-S-PEG3400-biotin) by Bd-cys dimers, aliquots of these
preparations were analyzed by SDS–PAGE in reducing conditions
(i.e., dilution in buffer containing b-ME prior to loading onto the
gel) or nonreducing conditions (i.e., buffer lacking b-ME). Fig. 1A
illustrates data obtained in nonreducing conditions. Shown in lane
1 are results obtained for afﬁnity-puriﬁed Bd-cys. Lanes 2 to 4
show samples resulting from conjugation of the afﬁnity-puriﬁed
Bd-cys with maleimide-FL (lane 2), with FITC (lane 3), and with
maleimide-PEG3400-biotin (lane 4). These four samples contained
varying contributions from the dimer form of Bd-cys. Speciﬁcally,
as normalized to the combined density of the monomer and dimer
bands in a given lane, the dimer contributions in lanes 1 to 4 were
0.63, 0.25, 0.65, and 0.51, respectively. When the samples were
treated with b-ME prior to loading onto the gel (Fig. 1B), Bd-cys
was efﬁciently converted to monomer (normalized dimer contri-
butions of 60.1 for all lanes), consistent with the reduction of
disulﬁde bonds under the reducing conditions. Together, the re-
sults in Fig. 1A and B indicate that, following the standard treat-
ment with DTT as part of the preparation of the conjugates,
contaminating dimers remained in the ﬁnal product. This contam-
ination presumably reﬂected incomplete reduction by DTT and/or
the re-formation of dimerizing disulﬁde linkages during subse-
quent washes (which removed DTT) or during the conjugation
reaction (which was carried out in the absence of DTT). As a mea-
sure of the possible effects of dimer in the conjugate preparations,
the examination of Bd-cys-binding kinetics and of oocyte surface
interaction (see below) also included tests of preparations that,
by design, were dominated by dimer (i.e., not subjected to the
reducing preparative step).
To compare the IgG-binding afﬁnity of the Bd-cys construct
with that of SpA, and because guinea pig and rabbit IgGs were used
as the two investigated anti-GABAA subunit antibodies, we em-
ployed ELISA to assess the binding of Bd-cys monomer and dimer
to HRP-conjugated guinea pig IgG and rabbit IgG. Fig. 2A shows
net absorbance data (sample minus blank; see Materials and Meth-
ods) obtained for the binding of Bd-cys-S-FL monomer and SpA to
the HRP-conjugated IgG preparations. There were no signiﬁcant
differences in binding of Bd-cys-S-FL and SpA to HRP–guinea pig
IgG (0.91 ± 0.14 and 0.84 ± 0.04, respectively, P = 0.43) or to HRP–
rabbit IgG (1.13 ± 0.11 and 1.25 ± 0.04, respectively, P = 0.16).
Furthermore, net absorbance data obtained for the binding of both
Bd-cys-S-FL and SpA to both IgG preparations signiﬁcantly
exceeded those obtained from TBST controls from which Bd-
cys-S-FL or SpA was omitted (P = 7.2  105 and 2.45  105
[HRP–guinea pig IgG] and 2.42  104 and 1.28  105 [HRP–
rabbit IgG], respectively). Fig. 2B shows that, as with monomer
Bd-cys-S-FL in Fig. 2A, net absorbance for the binding of unlabeledFig.1. SDS–PAGE analysis. Proﬁles were obtained for afﬁnity-puriﬁed Bd-cys (lane 1), B
(lane 4). Samples were prepared in buffer lacking b-ME (A) or containing 5% (v/v) b-M
molecular weight (kDa) of standards. Dimer bands were present in the proﬁles of all thr
buffer contained b-ME (B).Bd-cys dimer and FL-labeled Bd-cys dimer to the IgG preparations
also signiﬁcantly exceeded those of TBST controls (P = 2.0  106
and 2.9  104 [HRP–guinea pig IgG] and 1.8  107 and
1.8  105 [HRP–rabbit IgG], respectively). Although higher than
the net absorbance for TBST controls, net absorbances for thed-cys-S-FL (lane 2), FL-labeled Bd-cys dimer (lane 3), and Bd-cys-S-PEG3400-biotin
E (B) immediately prior to electrophoresis (4–20% acrylamide Tris–HCl gel). MW:
ee conjugates (lanes 2–4) in nonreducing conditions (A), but not when the loading
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IgG and 0.21 ± 0.01 for HRP–rabbit IgG) were signiﬁcantly less than
those for unlabeled Bd-cys dimer (0.85 ± 0.04 for HRP–guinea pig
IgG and 0.98 ± 0.02 for HRP–rabbit IgG) and for SpA (0.84 ± 0.04
for HRP–guinea pig IgG and 1.25 ± 0.04 for HRP–rabbit IgG)
(P < 0.001).
Afﬁnity and kinetics of binding to anti-GABAA-q1 and anti-GABAA-a1
antibodiesSurface plasmon resonance
Using a streptavidin-coated chip, we examined binding of the
anti-GABAA-q1 and anti-GABAA-a1 antibodies to a surface immo-
bilized with Bd-cys-S-PEG3400-biotin. The top panel of Fig. 3
shows results obtained when anti-GABAA-a1 (arrow 1) and anti-
GABAA-q1 (arrow 3) were introduced to a ﬂow cell containing
immobilized Bd-cys-S-PEG3400-biotin. The response produced by
antibody binding for anti-GABAA-a1 and anti-GABAA-q1 amounted
to approximately 2000 and 800 RU, respectively. The larger size of
the response to anti-GABAA-a1 is consistent with the somewhat
stronger afﬁnity of Bd-cys-S-PEG3400-biotin to the anti-GABAA-a1
described in Fig. 2A. Also shown in the top panel of Fig. 3 are
responses to rat IgG2a (arrow 2) and chicken IgY (arrow 4), twoFig.3. SPR sensograms (responses in RU) for binding of IgG and IgY antibodies. (A)
Bd-cys-S-PEG3400-biotin capture agent. Here and in panel B, arrows indicate the
times of introduction of anti-GABAA-a1 rabbit IgG (1), rat IgG2a (2), anti-GABAA-q1
guinea pig IgG (3), chicken IgY (4), and anti-insulin chicken IgY (5). (B) Insulin-
biotin capture agent. In both panels A and B, sensogram electronic spikes of 64 s
duration have been removed. Thus, surface-bound Bd-cys-S-PEG3400-biotin spe-
ciﬁcally binds anti-GABAA-a1 IgG and anti-GABAA-q1 IgG.types of immunoglobulin known not to be reactive with SpA
[3,31]; no substantial signal was produced with either of these
immunoglobulins or with chicken anti-insulin IgY (arrow 5; see
below). The bottom panel of Fig. 3 shows results from an experi-
ment in which insulin-biotin was used as a control capture agent.
Here, chicken anti-insulin IgY (positive control) showed a substan-
tial signal, but neither anti-GABAA-a1 (arrow 1), anti-GABAA-q1
(arrow 3), rat IgG2a (control; arrow 2), nor chicken IgY (control; ar-
row 4) produced a signiﬁcant signal. Overall, the Fig. 3 data indi-
cate a speciﬁcity of interaction of the Bd-cys monomer with the
two investigated anti-GABAA subunit antibodies.
Binding afﬁnities and kinetics of the interactions of anti-GABAA-q1
and anti-GABAA-a1 antibodies with Bd-cys-S-PEG3400-biotin
were investigated over the concentration range of 0.625 to 20 nM
(10-ll/min ﬂow rate and 240-s incubation time). To test for the
possible inﬂuence of a mass transfer effect (i.e., of antibody ﬂow
rate) [32] on the kinetics of interaction of Bd-cys-S-PEG3400-biotin
with the anti-GABAA subunit antibodies, data were obtained with
2 nM antibody at varying ﬂow rates (5, 15, and 75 ll/min). Binding
proﬁles obtained with the three ﬂow rates produced responses
within the range of 43.5 to 45.4 RU, indicating an essential inde-
pendence of binding kinetics on ﬂow rate and, thus, a minimal ef-
fect of mass transport. Global v2 analysis of the data yielded
0.27 ± 0.18 and 1.9 ± 0.56 for the interaction of Bd-cys-S-
PEG3400-biotin with anti-GABAA-q1 and anti-GABAA-a1, respec-
tively (mean ± SD of v2 determinations in three experiments for
each antibody). Analysis through the Langmuir model also yielded
standard errors (SEs) for the investigated parameter; the SE determi-
nations in all cases represented less than 10% of the average value.
Fig. 4 shows two representative plots for the binding of
anti-GABAA-q1 (upper plot) and anti-GABAA-a1 (bottom plot) to
Bd-cys-S-PEG3400-biotin that was immobilized on a streptavidin-
coated ﬂow cell. Each plot shows the response (RU) versus time
(s) at ﬁve or six different concentrations (triplicate samples at each
concentration) of the anti-GABAA-q1 antibody (upper plot) and
anti-GABAA-a1 antibody (bottom plot): 0.625, 1.25, 2.5, 5.0, 10.0,
and 20.0 nM. The plots also show the ﬁtting of 1:1 ratio binding
curves to the sensogram data using Biacore evaluation software.
The results indicate a close ﬁt of the binding curves to the senso-
grams obtained for anti-GABAA-q1 and anti-GABAA-a1 antibodies.
Table 1 shows KD values of 6.4 ± 1.9 and 0.4 ± 0.1 nM determined
for the interaction of Bd-cys-S-PEG3400-biotin with anti-GABAA-
q1 and anti-GABAA-a1, respectively. These KD values, in addition
to ka and kd data in Table 1, indicate high afﬁnity of this Bd-cys
monomer conjugate for anti-GABAA-q1 guinea pig IgG and anti-
GABAA-a1 rabbit IgG. The ka and KD values for the binding of Bd-
cys-S-PEG3400-biotin to anti-GABAA-a1 rabbit IgG indicate
slightly higher afﬁnity for this IgG than for the guinea pig IgG. Data
obtained with the addition of rat IgG2a and chicken IgY negative
controls to immobilized Bd-cys-S-PEG3400-biotin and insulin-biotin,
as well as the addition of the rabbit anti-GABAA-a1 IgG and guinea
pig anti-GABAA-q1 IgG to immobilized insulin-biotin, showed no
change in the response and, thus, indicated the absence of binding.
Fluorescence anisotropy
In FA experiments, we investigated the binding of (monomeric)
Bd-cys-S-FL, FL-labeled Bd-cys dimer, and (as a negative control)
FL-labeled ubiquitin to anti-GABAA-q1 and anti-GABAA-a1 as well
as to (negative controls) rat IgG2a and chicken IgY. Figs. 5A and B
show data for referenced/normalized anisotropy as a function of
antibody concentration (nM) for the binding of Bd-cys-S-FL to
anti-GABAA-q1 and anti-GABAA-a1, respectively. Analysis of these
data through Eq. (1) yielded EC50 values of 65 and 18 nM, respec-
tively (Table 1). Similarly, Fig. 5C and D illustrate plots of refer-
enced/normalized anisotropy versus antibody concentration for
the binding of FL-labeled Bd-cys dimer to anti-GABAA-q1 and
Fig.4. SPR sensograms (responses in RU) for kinetics of binding of anti-GABAA-q1
and anti-GABAA-a1 to immobilized Bd-cys-S-PEG3400-biotin. (A) Red: sensograms
obtained with anti-GABAA-q1 at 20, 10, 5, 2.5, 1.25, and 0.625 nM. Black: ﬁtted
curves obtained using Biacore software in a 1:1 binding analysis. (B) Sensograms
(red) and ﬁtted curves (black) obtained with the addition of anti-GABAA-a1 at 10, 5,
2.5, 1.25, and 0.625 nM. Binding kinetics of both antibodies to Bd-cys-S-PEG3400-
biotin are well described by Langmuir 1:1 binding analysis (see Materials and
Methods).
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values of 93 and 25 nM, respectively (Table 1). The Fig. 5D and
Table 1 results describing the interaction of FL-labeled Bd-cys
dimer with anti-GABAA-a1 should be taken as only a relatively rough
estimate because the absolute range of FA signal amplitudes ob-
tained for this interaction was relatively small (see Materials and
Methods text noting excursions of ﬁtted curves in the FA analysis).
We furthermore examined, by FA, the binding of Bd-cys-S-FL and
FL-labeled Bd-cys dimer to control immunoglobulins that do notTable 1
KD, ka, kd, and EC50 values.
Row Method Preparation Param
1 SPR Bd-cys-S-PEG3400-biotin KD (nM
2 SPR Bd-cys-S-PEG3400-biotin ka (M
3 SPR Bd-cys-S-PEG3400-biotin kd (s
4 FA Bd-cys-S-FL EC50 (
5 FA FL-labeled Bd-cys dimer EC50 (
Note: Rows 1 to 3: SPR determinations of binding constant (KD), association rate constant
GABAA-a1 to Bd-cys-S-PEG3400-biotin capture agent. Data for a given antibody were ob
antibody concentration. Rows 4 and 5: FA determinations of EC50 for binding of Bd-cys-
EC50 values were derived from Eq. (1) ﬁtting to data obtained in one (anti-GABAA-q1) o
concentrations of antibody.bind to SpA (rat IgG2a and chicken IgY) [3]. Shown in Fig. 5E are
raw data for anisotropy (mA) versus antibody concentration (nM)
obtained for the binding of Bd-cys-S-FL (closed symbols) and FL-
labeled Bd-cys dimer (open symbols) to rat IgG2a (circles) and
chicken IgY (triangles). By contrast with results obtained for bind-
ing to anti-GABAA-q1 and anti-GABAA-a1, none of the four condi-
tions examined in Fig. 5E yielded a systematic increase in
anisotropy with increasing antibody concentration. Analysis of
the data failed to yield a smooth function of substantial ordinate
excursion; thus, the data could not be normalized as in Fig. 5A–
D. Control experiments (Fig. 5F) testing the binding of FL-labeled
ubiquitin (8.5 kDa) to anti-GABAA-a1, rat IgG2a, and chicken IgY
also failed to yield a systematic increase in anisotropy with
increasing antibody concentrations.
Binding of B-domain/IgG to oocytes expressing GABAA receptors
By ﬂuorescence microscopy, we investigated the interaction of
Bd-cys monomer conjugates with anti-GABAA subunit antibodies
that were prebound to the surface membrane of Xenopus oocytes
expressing homomeric GABAA-q1 and a1b2c2 GABAA receptors
(Fig. 6). In the experiment described by column 1 of Fig. 6A, a
GABAA-q1-expressing oocyte was treated, sequentially, with anti-
GABAA-q1 guinea pig IgG, Bd-cys-S-PEG3400-biotin, and streptavi-
din-DyLight 488 (see Materials and Methods). This treatment led
to the appearance of a ﬂuorescence halo at the surface membrane
of the (approximately spherical) oocyte. Columns 2 and 3 of Fig. 6A
shows results obtained from two control oocytes: a GABAA-q1-
expressing oocyte that was treated only with Bd-cys-S-PEG3400-
biotin and streptavidin-DyLight 488 (i.e., primary antibody
omitted) (column 2) and a nonexpressing oocyte that received the
same treatment as the oocyte of column 1. As illustrated in the
images in columns 2 and 3, both control preparations exhibited lit-
tle, if any, ﬂuorescence halo. In summary, the Fig. 6A data indicate
the binding of anti-GABAA-q1 antibody to the GABAA-q1-express-
ing oocyte and the binding of Bd-cys-S-PEG3400-biotin to the
receptor-bound primary antibody. As shown in Fig. 6B, treatment
of a1b2c2 GABAA-expressing oocytes with Bd-cys-S-PEG3400-bio-
tin similarly indicated speciﬁc binding of the Bd-cys-S-PEG3400-
biotin to receptor-bound anti-GABAA-a1 antibody. In addition,
FL-labeled Bd-cys dimer exhibited speciﬁc binding to receptor-
bound anti-GABAA-q1 and anti-GABAA-a1 IgG (Fig. 6C and D).Discussion
The current study has described the preparation of Bd-cys of
SpA and, in combination with IgG antibodies, the investigation of
Bd-cys as a scaffold for localizing compounds of interest to oo-
cyte-expressed q1 and a1b2c2 GABAA receptors. The results show
that when Bd-cys is conjugated with either maleimide-FL or malei-
mide-PEG3400-biotin, binding afﬁnities of the conjugate foreter Anti-GABAA-q1 Anti-GABAA-a1
) 6.4 ± 1.9 0.4 ± 0.1
1 s1) 2.1  105 ± 0.3  105 1.3  106 ± 5.0  104
1) 1.3  103 ± 2.3  104 4.8  104 ± 1.0  104
nM) 65 18
nM) 93 25
(ka), and dissociation rate constant (kd), for the binding of anti-GABAA-q1 and anti-
tained in three experiments, each involving triplicate samples at each investigated
S-FL monomer and FL-labeled Bd-cys dimer to anti-GABAA-q1 and anti-GABAA-a1.
r two (anti-GABAA-a1) experiments, each involving triplicate samples at each of 14
Fig.5. Binding of Bd-cys preparations to anti-GABAA subunit antibodies determined by FA. The horizontal axis in each panel represents concentration of the tested antibody.
(A–D) Referenced/normalized anisotropy in relation to antibody concentration (means ± SDs of values obtained in at least two experiments, each involving duplicate/
triplicate samples). (A) Bd-cys-S-FL with anti-GABAA-q1. Here and in panels B to D, curves illustrate Eq. (1) ﬁtted to the data. (B) Bd-cys-S-FL with anti-GABAA-a1. (C) FL-
labeled Bd-cys dimer with anti-GABAA-q1. (D) FL-labeled Bd-cys dimer with anti-GABAA-a1. (E and F) Anisotropy (mA) in relation to antibody concentration (means ± SDs of
values obtained in one experiment, each involving triplicate samples). (E) Anisotropy (mA) for Bd-cys preparations with control antibodies. Mixtures were Bd-cys-S-FL with
rat IgG2a (ﬁlled circles), Bd-cys-S-FL with chicken IgY (ﬁlled triangles), FL-labeled Bd-cys dimer with rat IgG2a (open circles), and FL-labeled Bd-cys dimer with chicken IgY
(open triangles). (F) Anisotropy (mA) for ubiquitin-FL with anti-GABAA-a1 (open circles), rat IgG2a (open triangles), and chicken IgY (open diamonds). An increase in
anisotropy with antibody concentration occurred only when the antibody incubated with the Bd preparation was anti-GABAA-q1 or anti-GABAA-a1.
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exhibited by full-length SpA (Fig. 2A and B). This ﬁnding, along
with the observed binding of Bd-cys-S-PEG3400-biotin/IgG com-
plex to oocyte-expressed q1 and a1b2c2 GABAA receptors
(Fig. 5), provides direct evidence that C-terminal cysteine insertion
and ligand conjugation preserve a robust afﬁnity of Bd for IgG
in vitro and in a receptor-containing cell membrane environment.
The SPR and FA results provide quantitative information on the
Bd-cys/IgG interaction. For the binding of Bd-cys-S-PEG3400-bio-
tin to anti-GABAA-q1 and anti-GABAA-a1, SPR data yielded KD val-
ues of 6.4 ± 1.9 and 0.4 ± 0.1 nM, respectively, and ka values of
2.1  105 ± 0.3  105 and 1.3  106 ± 5.0  104 M1 s1, respec-
tively (Table 1), consistent with previously reported values for
SpA and its domains [5,11,33–35]. The FA experiments yielded
EC50 values of 65 and 18 nM for the binding of the Bd-cys-S-FL
monomer to guinea pig anti-GABAA-q1 and rabbit anti-GABAA-a1
antibodies, respectively (Table 1). These nM-range values of KD
and EC50 indicate strong afﬁnity of the Bd-cys conjugate for the
two antibodies and are in agreement with the range of reported
values for the unlabeled and cysteine-free SpA, Bd, and other single
(and double) domains (2–70 nM) [5,33,36,37].
Previous studies employing radioimmunoassay have found that
the afﬁnities of SpA for guinea pig and rabbit IgG are similar[3,31,38]. However, the KD and EC50 determinations from the SPR
and FA experiments, respectively, indicate that the afﬁnity of Bd-
cys conjugates for the anti-GABAA-a1 antibody exceeds that for
the anti-GABAA-q1 antibody (Fig. 3A, Fig. 5A–D, and Table 1). This
relationship is also consistent with the results obtained by ELISA
(Fig. 2). The higher afﬁnity of Bd-cys for the anti-GABAA-a1 could
reﬂect a tighter binding of SpA (and its domains) to rabbit IgG as
compared with guinea pig IgG. That is, because SpA and its do-
mains bind to the Fc fragment and not the Fab fragment of IgG,
the binding of SpA and Bd to IgG is species and isotype dependent.
Alternatively, the evident difference in relative afﬁnity for anti-
GABAA-a1 versus anti-GABAA-q1 determined by SPR and FA could
reﬂect a differential sensitivity of the two analytical techniques to
signals arising from complexes in which anti-GABAA-a1 and anti-
GABAA-q1 participate.
The current study included tests of the activity of Bd-cys dimer,
a moiety present in Bd-cys monomer preparations (Fig. 1). The FA
data indicate that FL-labeled Bd-cys dimer has substantial afﬁnity
for the investigated anti-GABAA-q1 and anti-GABAA-a1 antibodies,
although the afﬁnity of the dimer for a given antibody appears less
than that exhibited by the Bd-cys monomer preparation (Fig. 5).
This somewhat lower antibody-binding afﬁnity of FL-labeled dimer
might be a consequence of masking, by the FL label, of residues
Fig.6. Binding of Bd-cys preparations and anti-GABAA subunit antibodies to GABAA-expressing oocytes. (A) GABAA-q1-expressing oocyte with anti-GABAA-q1, Bd-cys-S-
PEG3400-biotin, and streptavidin-DyLight 488 (column 1) or with Bd-cys-S-PEG3400-biotin and streptavidin-DyLight 488 only (column 2). Column 3: nonexpressing oocyte
with same treatment as in column 1. (B) a1b2c2 GABAA-expressing oocyte with anti-GABAA-a1, Bd-cys-S-PEG3400-biotin, and streptavidin-DyLight 488 (column 1) or with
Bd-cys-S-PEG3400-biotin and streptavidin-DyLight 488 only (column 2). Column 3: nonexpressing oocyte with same treatment as in column 1. (C) GABAA-q1-expressing
oocyte with anti-GABAA-q1 and FL-labeled Bd-cys dimer (column 1) or with FL-labeled Bd-cys dimer only (column 2). Column 3: nonexpressing oocyte with same treatment
as in column 1. (D) a1b2c2 GABAA-expressing oocyte with anti-GABAA-a1 and FL-labeled Bd-cys dimer (column 1) or with FL-labeled Bd-cys dimer only (column 2). Column
3: nonexpressing oocyte with same treatment as in column 1. Similar microscope acquisition settings were used for all conditions. For visual clarity, a ﬁxed adjustment of
brightness and contrast was applied to all images of panels C and D. Scale bar = 150 lm. The data show that the binding of Bd-cys-S-PEG3400-biotin (A and B) and of FL-
labeled Bd-cys dimer (C and D) to the oocyte surface membrane depends on both the expression of GABAA receptor (GABAA-q1 in panels A and C; a1b2c2 GABAA in panels B
and D) and the presence of the cognate antibody.
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tion, the ELISA results of Fig. 2 indicate signiﬁcantly lower net
absorbance values for the FL-labeled Bd-cys dimer than for unla-
beled Bd-cys dimer and the FL-labeled monomer, indicating rela-
tively weak antibody binding for the FL-labeled Bd-cys dimer.
The larger difference observed in the ELISA assay for the anti-
body-binding afﬁnities of FL-labeled Bd-cys dimer versus FL-
labeled monomer could be due to the use of different antibodies
in the ELISA versus FA experiments. Because the streptavidin-
coated surface of the SPR ﬂow cell captured only (monomeric)
Bd-cys-S-PEG3400-biotin, Bd-cys dimer did not contribute to the
detected SPR signals. In the FA experiments testing Bd-cys-S-FL,
contaminating Bd-cys dimer (which lacked cys-S-conjugated FL)
was not a reporting moiety but presumably bound antibodies in
solution and rendered them unavailable for binding to the
Bd-cys-S-FL. The evident variation among samples in the amount
of dimer present (Fig. 1) could be due to differences in preparative
conditions or to the difference in the maleimide compounds added
(i.e., maleimide-FL vs. maleimide-PEG3400-biotin). A bulkier
maleimide compound, for example, could exhibit a slower reaction
with monomeric Bd-cys, allowing more time for reduced sulfhy-
dryl groups to combine and form dimers.
The current ﬁndings extend the approach described by
Mazzucchelli and coworkers [21] and demonstrate speciﬁcally
the ability of Bd-cys, in combination with an SpA-binding antibody,
to localize Bd-cys-bound compounds at transmembrane ion chan-
nels. In contrast to direct functionalization of the antibody through
technologies that often yield conjugates of multiple and variable
valency (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
[EDC] coupling of the ligand to lysine residues), the approach stud-
ied here enables localization of the ligand at a single deﬁned site on
the Bd-cys scaffold and, thus (given the speciﬁcities of Bd’s
attachment to IgG and of IgG’s attachment to the target protein),
a uniformity of spatial positioning of the ligand relative to the
target protein’s structure. Of particular note is our ﬁnding that
conjugation of Bd-cys with a long-chain PEG moiety (maleimide-
PEG3400-biotin) preserves robust binding of the conjugate/antibody complex to the target membrane protein. That is, both
high-afﬁnity interaction of the Bd-cys scaffold for anti-GABAA
antibody and high-afﬁnity interaction of the complex with the
investigated GABAA receptors are maintained in the presence of
the long, highly ﬂexible PEG3400. Particularly in cases where the
cysteine site of the Bd-cys may be relatively distant from the target
protein’s ligand-binding site, Bd-cys/antibody complexes that em-
ploy a long-chain linker for ligand tethering to Bd-cys may prove to
be useful for achieving localized physiological control of GABA
receptors as well as other transmembrane ion channels [18–20].Acknowledgments
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